Cimetidine

Generic Name: Cimetidine

Brand Names: Good Sense Heartburn Relief, Tagamet

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₆N_₆S

CAS Number: 51481-61-9

Unique Ingredient Identifier: 80061L1WGD

Background: A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.

Indication: Cimetidine is indicated to reduce gastric acid secretion and to treat the following disease states: duodenal ulcers, non-malignant gastric ulcers, gastroesophageal reflux disease, and pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis, and multiple endocrine adenomas. It is indicated for prophylaxis of recurrent gastric or duodenal ulcers, as adjunctive therapy in the management of cystic fibrosis in children, and to treat NSAID induced lesions and gastrointestinal symptoms.

Associated Conditions: Cystic Fibrosis (CF), Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Gastrointestinal Symptoms, Heartburn, Active Duodenal ulcer, Benign gastric ulcers, Develop NSAID-induced gastric ulcers, Recurrent Ulcers, Duodenal and Gastric

Clinical Trials

Drug Excretion in Breast Milk

Phase 4

Recruiting

Conditions: OCT1
Lactation
BCRP
Drugs in Breast Milk
Postpartum
Mammary Drug Transporters

Interventions: Drug: Cimetidine 200 MG

First Posted Date: 2023-09-28

Last Posted Date: 2024-08-06

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT06056583

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

The Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects

Phase 1

Completed

Conditions: PHN - Post-Herpetic Neuritis

Interventions: Drug: HSK16149，probenecid, cimetidine

First Posted Date: 2023-05-31

Last Posted Date: 2023-12-07

Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Target Recruit Count: 47

Registration Number: NCT05881811

Locations: 🇨🇳
Beijing Jishuitan Hoispital, Beijing, China

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

Early Phase 1

Recruiting

Conditions: Interaction
Endogenous Biomarkers

Interventions: Drug: Furosemide Oral Liquid Product
Drug: MetFORMIN Oral Solution
Drug: Cimetidine 400 MG
Drug: Probenecid 500 MG

First Posted Date: 2022-05-09

Last Posted Date: 2024-12-19

Lead Sponsor: Washington State University

Target Recruit Count: 32

Registration Number: NCT05365451

Locations: 🇺🇸
Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States

Effect of Oral Cimetidine in the Protoporphyrias

Phase 2

Completed

Conditions: Erythropoietic Protoporphyria
X-linked Protoporphyria

Interventions: Drug: Placebo
Drug: Cimetidine

First Posted Date: 2021-08-25

Last Posted Date: 2025-04-27

Lead Sponsor: Amy K. Dickey, M.D.

Target Recruit Count: 26

Registration Number: NCT05020184

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2

Completed

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8